Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene.
OBJECTIVE
We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective estrogen receptor modulators (SERMs) has not been examined before.


METHODS
This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials.


METHODS
From both studies we examined only the Danish subpopulation. Study 1 included 133 women treated with placebo or levormeloxifene in four different doses for 12 months, and study 2 included 248 women treated with raloxifene in three different doses or placebo for 24 months.


METHODS
Bone mineral density (BMD) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline.


RESULTS
We found a significant correlation between the increase in BMD of the spine and hip and the decrease in total cholesterol and low-density lipoprotein.


CONCLUSIONS
Our study showed that, in healthy postmenopausal women, the women with the greatest response in BMD were also those with the most favorable response in lipid profile during treatment with SERMs.
Bloch-Thomsen
A
A
Center for Clinical and Basic Research, Ballerup, Denmark.
Silvestri
S
S
Christiansen
C
C
Bjarnason
N H
NH
D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause; D011759:Pyrrolidines / Q000494:pharmacology*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
D008078:Cholesterol, LDL; D008055:Lipids; D011759:Pyrrolidines; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; C108255:levormeloxifene; D002784:Cholesterol